Takeda, CanBas Begin Phase II Trials For Malignant Pleural Mesothelioma Drug
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Osaka-based Takeda and its U.S. subsidiary Millennium, jointly with a Japanese pharmaceutical venture, CanBas Co., have begun Phase II trials of malignant pleural mesothelioma drug CBP501 in the United States. The drug's advancement could eventually save millions of people that have been exposed to deadly asbestos, the company said
You may also be interested in...
DMC Recommends Resuming Phase III Takeda, Millennium, Amgen MONET1 Trial
TOKYO - An independent data monitoring committee has recommended that Takeda/Amgen/Millennium's MONET1 Phase III trial resume enrollment of patients with non-squamous non-small cell lung cancer, following a three-month enrollment suspension, a Takeda spokesman said Feb. 12
DMC Recommends Resuming Phase III Takeda, Millennium, Amgen MONET1 Trial
TOKYO - An independent data monitoring committee has recommended that Takeda/Amgen/Millennium's MONET1 Phase III trial resume enrollment of patients with non-squamous non-small cell lung cancer, following a three-month enrollment suspension, a Takeda spokesman said Feb. 12
Takeda Readying To Launch Acid Reflux Med Kapidex Within A Month
Japanese drug maker looks to dexlansoprazole to help offset loses when Prevacid and anti-diabetic Actos go off patent this year.